Anamorelin
As of the edition of 20 October 2026, Anamorelin is a small molecule: marketed, first approved in 2021 (JP); acts on GHSR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2021
- Kind
- Small molecule
- Brand name
- Adlumiz
- First approved
- 22 January 2021 (JP)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Ono Pharmaceutical
- Registered trials
- 11, 2 stopped early
- Disease areas
- Cancer; Lungs and airways; Digestive system; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| GHSR | Growth hormone secretagogue receptor type 1 | Q92847 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 6 | 3 | 1 | 2 |
| Phase 3 | 5 | 4 | 1 | 0 |
| All trials | 11 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Ono Pharmaceutical | Applicant | 2021 to now |